Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.
Amphotericin B (AmB) has been in clinical use for more than 30 yr but has remained the most effective drug for treatment of serious fungal infections. Its use has increased in recent years, as the result of increases in aggressive intensive care support and increased numbers of immunocompromised patients. Nephrotoxic manifestations are common, and this is the major factor limiting the clinical use of the drug. A number of recent studies have contributed to a better understanding of the mechanism by which AmB exerts its nephrotoxic effect. AmB alters cell membrane permeability and probably as a consequence alters tubular and vascular smooth muscle cell function, leading to various tubular transport defects and vasoconstriction. Decreased RBF appears to play a major role in AmB-induced reduction GFR, and recurrent ischemia may be the basis of permanent structural nephrotoxic effects. Salt loading is the only measure proven by controlled prospective study to ameliorate AmB nephrotoxicity in humans. Liposomal AmB and the formulation of an emulsion of AmB in lipid may provide a protective effect based on altering the affinity of AmB for mammalian cell membranes, while preserving high efficacy against fungal cells. However, further studies are needed to evaluate the efficacy and safety of these new AmB formulations.
Sawaya
B P
BP
Briggs
J P
JP
Schnermann
J
J
D000141:Acidosis, Renal Tubular / Q000139:chemically induced; D000666:Amphotericin B / Q000009:adverse effects*; D002463:Cell Membrane Permeability / Q000187:drug effects; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced*; D014661:Vasoconstriction / Q000187:drug effects
D000666:Amphotericin B